Jonas S. Jutzi

912 total citations
21 papers, 422 citations indexed

About

Jonas S. Jutzi is a scholar working on Genetics, Molecular Biology and Hematology. According to data from OpenAlex, Jonas S. Jutzi has authored 21 papers receiving a total of 422 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Genetics, 14 papers in Molecular Biology and 11 papers in Hematology. Recurrent topics in Jonas S. Jutzi's work include Myeloproliferative Neoplasms: Diagnosis and Treatment (14 papers), Acute Myeloid Leukemia Research (8 papers) and Eosinophilic Disorders and Syndromes (6 papers). Jonas S. Jutzi is often cited by papers focused on Myeloproliferative Neoplasms: Diagnosis and Treatment (14 papers), Acute Myeloid Leukemia Research (8 papers) and Eosinophilic Disorders and Syndromes (6 papers). Jonas S. Jutzi collaborates with scholars based in United States, Germany and Spain. Jonas S. Jutzi's co-authors include Heike L. Pahl, Ann Mullally, Christine Dierks, Heinz Gisslinger, Tariq I. Mughal, Hans Carl Hasselbalch, Jean‐Jacques Kiladjian, Tiziano Barbui, Francisco Cervantes and Rüdiger Hehlmann and has published in prestigious journals such as The Journal of Experimental Medicine, Blood and PLoS ONE.

In The Last Decade

Jonas S. Jutzi

20 papers receiving 422 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jonas S. Jutzi United States 10 282 250 238 109 37 21 422
Jiřı́ Schwarz Czechia 11 249 0.9× 245 1.0× 220 0.9× 64 0.6× 47 1.3× 36 403
Rodolphe Besancenot France 6 252 0.9× 227 0.9× 166 0.7× 88 0.8× 37 1.0× 9 348
Lawrence J. Breyfogle United States 5 271 1.0× 263 1.1× 232 1.0× 97 0.9× 33 0.9× 8 410
Hajime Akada United States 7 331 1.2× 266 1.1× 244 1.0× 101 0.9× 46 1.2× 12 437
Tina L. Hamilton United Kingdom 8 168 0.6× 206 0.8× 232 1.0× 39 0.4× 59 1.6× 8 344
Peter A. te Boekhorst Netherlands 6 238 0.8× 225 0.9× 126 0.5× 94 0.9× 14 0.4× 8 331
Alessandro M. Vannucchi Italy 9 355 1.3× 254 1.0× 256 1.1× 150 1.4× 15 0.4× 15 430
Ema Anastasiadou United States 6 121 0.4× 351 1.4× 254 1.1× 60 0.6× 53 1.4× 7 500
F.-X. Mahon France 11 268 1.0× 323 1.3× 68 0.3× 162 1.5× 34 0.9× 20 414
Klaudia Bagienski Austria 4 319 1.1× 268 1.1× 200 0.8× 115 1.1× 11 0.3× 7 365

Countries citing papers authored by Jonas S. Jutzi

Since Specialization
Citations

This map shows the geographic impact of Jonas S. Jutzi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jonas S. Jutzi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jonas S. Jutzi more than expected).

Fields of papers citing papers by Jonas S. Jutzi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jonas S. Jutzi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jonas S. Jutzi. The network helps show where Jonas S. Jutzi may publish in the future.

Co-authorship network of co-authors of Jonas S. Jutzi

This figure shows the co-authorship network connecting the top 25 collaborators of Jonas S. Jutzi. A scholar is included among the top collaborators of Jonas S. Jutzi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jonas S. Jutzi. Jonas S. Jutzi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Jutzi, Jonas S., et al.. (2025). Mutant Calreticulin in MPN: Mechanistic Insights and Therapeutic Implications. Current Hematologic Malignancy Reports. 20(1). 4–4. 1 indexed citations
2.
Müller, Anja, Judith M. Müller, Florian Perner, et al.. (2025). Lysine-specific demethylase 1 regulates hematopoietic stem cell expansion and myeloid cell differentiation. Cell Death and Disease. 16(1). 619–619. 1 indexed citations
3.
Jutzi, Jonas S., Jason A. Wampfler, Michèle J. Hoffmann, et al.. (2025). CAR T‐Cell Therapies for Patients With Relapsed and Refractory Aggressive Lymphomas: Real‐World Experiences From a Single Center on the Use of Radiotherapy. Hematological Oncology. 43(5). e70124–e70124.
4.
5.
6.
Hobbs, Gabriela, Haesook T. Kim, Mark A. Schroeder, et al.. (2023). Updated Findings of a Phase II Study of Ruxolitinib Pre-, during- and Post-Hematopoietic Stem Cell Transplantation for Patients with Primary or Secondary Myelofibrosis. Blood. 142(Supplement 1). 2103–2103. 6 indexed citations
7.
Jutzi, Jonas S., Anna E. Marneth, Ángel Guerra-Moreno, et al.. (2022). Whole-genome CRISPR screening identifies N-glycosylation as a genetic and therapeutic vulnerability in CALR-mutant MPNs. Blood. 140(11). 1291–1304. 11 indexed citations
8.
Jutzi, Jonas S., Anna E. Marneth, Ángel Guerra-Moreno, et al.. (2022). CALR-mutated cells are vulnerable to combined inhibition of the proteasome and the endoplasmic reticulum stress response. Leukemia. 37(2). 359–369. 13 indexed citations
9.
Pahl, Heike L., et al.. (2021). The Cross Marks the Spot: The Emerging Role of JmjC Domain-Containing Proteins in Myeloid Malignancies. Biomolecules. 11(12). 1911–1911. 9 indexed citations
10.
Marneth, Anna E., Jonas S. Jutzi, Ángel Guerra-Moreno, et al.. (2021). Whole-Genome CRISPR Screening Identifies N-Glycosylation As an Essential Pathway and a Potential Novel Therapeutic Target in CALR-Mutant MPN. Blood. 138(Supplement 1). 58–58. 1 indexed citations
11.
Heinemann, Johannes, et al.. (2020). Jmjd1c is dispensable for healthy adult hematopoiesis and Jak2V617F-driven myeloproliferative disease initiation in mice. PLoS ONE. 15(2). e0228362–e0228362. 5 indexed citations
12.
Jutzi, Jonas S. & Ann Mullally. (2020). Remodeling the Bone Marrow Microenvironment – A Proposal for Targeting Pro-inflammatory Contributors in MPN. Frontiers in Immunology. 11. 2093–2093. 17 indexed citations
13.
Müller, Alexandra, Julia Miriam Weiss, Jonas S. Jutzi, et al.. (2020). BCL-XL expression is essential for human erythropoiesis and engraftment of hematopoietic stem cells. Cell Death and Disease. 11(1). 8–8. 30 indexed citations
14.
Jutzi, Jonas S., S Kaiser, Doris Steinemann, et al.. (2019). Altered NFE2 activity predisposes to leukemic transformation and myelosarcoma with AML-specific aberrations. Blood. 133(16). 1766–1777. 20 indexed citations
15.
Gründer, Albert, Fengbiao Zhou, Jonas S. Jutzi, et al.. (2019). Enhanced expression of the sphingosine-1-phosphate-receptor-3 causes acute myelogenous leukemia in mice. Leukemia. 34(3). 721–734. 10 indexed citations
16.
Peeken, Jan C., Jonas S. Jutzi, Julius Wehrle, et al.. (2018). Epigenetic regulation of NFE2 overexpression in myeloproliferative neoplasms. Blood. 131(18). 2065–2073. 35 indexed citations
17.
Jutzi, Jonas S., Maria Kleppe, Jennifer Dias, et al.. (2018). LSD1 Inhibition Prolongs Survival in Mouse Models of MPN by Selectively Targeting the Disease Clone. HemaSphere. 2(3). e54–e54. 78 indexed citations
18.
Koschmieder, Steffen, Tariq I. Mughal, Hans Carl Hasselbalch, et al.. (2016). Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or both. Leukemia. 30(5). 1018–1024. 119 indexed citations
19.
Jutzi, Jonas S. & Heike L. Pahl. (2015). The Hen or the Egg: Inflammatory Aspects of Murine MPN Models. Mediators of Inflammation. 2015(1). 101987–101987. 9 indexed citations
20.
Jutzi, Jonas S., Ruzhica Bogeska, Gorica Nikoloski, et al.. (2013). MPN patients harbor recurrent truncating mutations in transcription factor NF-E2. The Journal of Experimental Medicine. 210(5). 1003–1019. 49 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jiřı́ Schwarz Breakdown of academic impact, for papers by Rodolphe Besancenot Breakdown of academic impact, for papers by Lawrence J. Breyfogle Breakdown of academic impact, for papers by Hajime Akada Breakdown of academic impact, for papers by Tina L. Hamilton Breakdown of academic impact, for papers by Peter A. te Boekhorst Breakdown of academic impact, for papers by Alessandro M. Vannucchi Breakdown of academic impact, for papers by Ema Anastasiadou Breakdown of academic impact, for papers by F.-X. Mahon Breakdown of academic impact, for papers by Klaudia Bagienski
Rankless by CCL
2026